Graphical Abstract Highlights d Invasive tumor fronts are enriched in rounded-amoeboid cancer cells high in Myosin II d Myosin II activity in these cells regulates an immunomodulatory secretome d The secreted cytokines and chemokines can induce tumorpromoting macrophages d ROCK-Myosin II and IL-1a/NF-kB cross-talk supports this secretory phenotype
SUMMARY
ROCK-Myosin II drives fast rounded-amoeboid migration in cancer cells during metastatic dissemination. Analysis of human melanoma biopsies revealed that amoeboid melanoma cells with high Myosin II activity are predominant in the invasive fronts of primary tumors in proximity to CD206 + CD163 + tumor-associated macrophages and vessels. Proteomic analysis shows that ROCK-Myosin II activity in amoeboid cancer cells controls an immunomodulatory secretome, enabling the recruitment of monocytes and their differentiation into tumor-promoting macrophages. Both amoeboid cancer cells and their associated macrophages support an abnormal vasculature, which ultimately facilitates tumor progression. Mechanistically, amoeboid cancer cells perpetuate their behavior via ROCK-Myosin II-driven IL-1a secretion and NF-kB activation. Using an array of tumor models, we show that high Myosin II activity in tumor cells reprograms the innate immune microenvironment to support tumor growth. We describe an unexpected role for Myosin II dynamics in cancer cells controlling myeloid function via secreted factors.
INTRODUCTION
Metastasis accounts for >90% of cancer-related deaths, indicating an urgent need for clinical management (Friedl and Wolf, 2003) . To leave the primary tumor, cancer cells disseminate using different migration modes (Pandya et al., 2017) . Although collective cell migration is important for tissue remodeling, single-cell migration (rounded-amoeboid or elongatedmesenchymal) allows transport, both locally and to distant sites along with invasion through basement membranes (Giampieri et al., 2009) . Actomyosin contractility driven by Myosin II controls cytoskeletal remodeling and tumor dissemination (Rodriguez-Hernandez et al., 2016) . ROCK can directly phosphorylate myosin light chain 2 (MLC2) or indirectly decrease Myosin phosphatase (MYPT) activity increasing MLC2 phosphorylation (Ito et al., 2004) . ROCK can also activate LIMK, which phosphorylates and inactivates cofilin resulting in F-actin stabilization (Yang et al., 1998) . High levels of actomyosin contractility driven by Myosin II are key to sustain amoeboid bleb-based migration Sahai and Marshall, 2003; Sanz-Moreno et al., 2011) . Intravital imaging in melanoma and breast cancer mouse xenografts revealed amoeboid migration is favored in the tumor invasive fronts (IFs) (Herraiz et al., 2015; Sanz-Moreno et al., 2008 Tozluo glu et al., 2013) .
On the other hand, cancer-associated inflammation promotes tumorigenesis at many levels. Inflammation is enabled by the secretion of multiple factors and the recruitment of immune cells, like monocytes (Coussens and Werb, 2002) . Monocytes differentiate to macrophages, which can change their phenotypes responding to microenvironmental signals. Classically activated macrophages are induced in response to pro-inflammatory stimuli, such as lipopolysaccharides (LPS) or interferon gamma (IFN-g) and exhibit cytotoxic functions. Cytokines such as interleukin (IL)-4, IL-13, and IL-10, transforming growth factor beta (TGF-b), and/or glucocorticoids can support alternatively activated macrophages (AAMs) that promote tissue repair and tumor progression (Gordon, 2003) .
Here, we investigated how Myosin II activity in cancer cells controls the secretion of factors regulating the tumor microenvironment (TME) via the establishment of a cross-talk with proinflammatory nuclear factor kB (NF-kB).
RESULTS

Invasive Fronts of Human Melanomas Are Enriched in Amoeboid Melanoma Cells Close to Macrophages and Blood Vessels
Using intravital imaging in xenograft melanoma models, we have previously reported an enrichment in amoeboid migration in the invasive edge of tumors (Herraiz et al., 2015; Sanz-Moreno et al., 2011) . To test whether this was recapitulated in human patient tissues, we evaluated human melanoma biopsies using a tissue microarray (40 human melanoma lesions, cohort A) and a smaller cohort (7 melanoma lesions, cohort B). For both cohorts, matched tumor body (TB) and IF were included. IFs of human primary melanomas were found enriched in rounded cancer cells independently of the morphology in the TB ( Figure 1A) . Importantly, we found a regional increase in phosphorylated MLC2 (p-MLC2) levels in the IF (Figure 1B) indicative of high Myosin II activity. Our data suggest that the combination of roundness and increased p-MLC2 can define the amoeboid contractile cancer phenotype accurately in patients' biopsies.
Interestingly, in both of our patient tissue cohorts, macrophages were a prominent population, in accordance with previous studies reporting that macrophages constitute up to 30% of the immune infiltrate in melanoma (Brö cker et al., 1988; Hussein, 2006) . Furthermore, high tumor-associated macrophage (TAM) infiltration has been associated to poor prognosis (Zhang et al., 2015) . We thus sought to identify regional differences in macrophage composition in patient cohort A. CD68 is a pan-macrophage marker, while CD163 and CD206 (Kakizaki et al., 2015) typify AAMs (Vogel et al., 2014) . We found no regional difference in CD68 + cells ( Figure 1C ). However, both CD163 + and CD206 + TAMs were enriched in the IFs of tumors (Figures 1D and 1E) . TAMs support angiogenesis (Chen et al., 2011) , while they are located in perivascular tumor areas (Wyckoff et al., 2007) . We observed elevated vessel density in the same tumor regions where macrophages were abundant (Figure 1F) . Similar results were observed in cohort B (Figures S1A-S1D) .
The TME in aggressive tumors may favor the formation of premetastatic ''invasive niches'' composed of cancer cells, endothelial cells, and macrophages (Joyce and Pollard, 2009) . Indeed, metastatic melanoma lesions were enriched in both rounded melanoma cells (Figure 1G ) and CD206 + TAMs (Figures 1H, S1E, and S1F) in proximity to blood vessels ( Figure 1I ). Using the Cancer Genome Atlas (TCGA) database, we found increased CD206 mRNA levels in metastatic versus primary human melanomas (n = 384) ( Figure 1J ). Furthermore, using Gene Expression Omnibus (GEO) database, we found a positive correlation between CD206 and CD31 mRNA levels in melanoma patients (n = 322) ( Figure S1G ). These data support the notion that these non-cancerous cellular components are upregulated in human melanoma.
Overall, the IFs of human melanomas are enriched in amoeboid melanoma cells, which are associated with a specific TME, the amoeboid-associated TME (AATME). Importantly, the TME found in metastatic sites mirrors the TME found in the IFs of melanomas, that is, the AATME ( Figure 1K ).
Myosin II Activity in Melanoma Cells Favors Secretion of Immunomodulatory Factors
Tumor cell-normal cell communication can be mediated by secreted factors (Melnikova and Bar-Eli, 2009 ). A375M2 are highly metastatic (Clark et al., 2000) rounded melanoma cells ($90% rounded ) with higher Myosin II activity ( Figure 2A ). A375M2 cells are derived from poorly metastatic A375P (Clark et al., 2000) more elongated melanoma cells (50% rounded, 50% elongated ) with lower Myosin II activity compared to A375M2 cells (Figure 2A ). Using a protein array consisting of 274 human chemokines, cytokines, growth factors, and matrix metalloproteinases, we found that 155 proteins were highly secreted by A375M2 cells compared to A375P cells ( Figure 2B ). These factors were sub-divided into 3 groups based on their fold change ( Figure 2B ). A375M2 cells were shown to secrete high levels of cytokines, such as IL-3, IL-4, IL-5, and IL-13. The amoeboid-melanoma secretome (A) . Values range from 0 (no staining) to 400 (very intense staining). (C-F) (Left) Quantification and (right) representative images of (C) CD68 + , (D) CD163 + , (E) CD206 + , and (F) CD31 + cells in TB and IF of primary melanomas. (G) Melanoma cell-shape score in primary and metastatic melanomas. (H and I) (Left) Quantification and (right) representative images of (H) CD206 + and (I) CD31 + cells in primary and metastatic melanomas. (J) mRNA levels of CD206 in primary (n = 68) and metastatic (n = 316) melanomas. Raw data were obtained from TCGA. (K) Schematic: IF and metastatic site of human melanoma. In (A)-(I), n = 24 primary and n = 16 metastatic melanomas. Scale bars, 200 mm for the tumor cores, 50 mm for all the focused images except (A) for the focused images showing the score where scale bar is 5 mm. All data are presented per patient. Average has been taken from 4 tumor cores per TB and 4 tumor cores per IF. In (A)-(F), matched TB and IF from same patients are presented. In (A)-(I), boxplots show min to max values. In (J) , dot blot shows mean ± SEM. In (A)-(F), Wilcoxon matched-pairs signed-rank test is shown. In (G)- (J) , t test is shown. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S1 and Tables S3 and S4 appears to be skewed toward a pro-inflammatory signature typically associated with tumor progression ( Figure S2A ). We confirmed by ELISA that A375M2 cells secreted high levels of pro-inflammatory IL-1a, IL-8, and immunosuppressive IL-10 and TGF-b ( Figure 2C ). To expand our observations to the clinical setting, GEO (n = 421) and TCGA (n = 354) databases were used to evaluate mRNA levels of some highly secreted factors by A375M2 cells. IL-1a, IL-10, TGF-b, IL-8, and IL-4 mRNA were all upregulated during melanoma progression with a significant increase in metastatic compared to primary human melanomas ( Figure S2B ) suggesting transcriptional regulation. We confirmed that protein secretion was Myosin II dependent since A375M2 cells depleted from MLC2 secreted significantly less cytokines and chemokines (Figures 2D and S2C) . ROCK is a key regulator of Myosin II activity (Amano et al., 1996) , and, as such, A375M2 cells depleted from ROCK1/2 via RNAi had decreased protein secretion (Figures 2E and S2D) . These results were confirmed using 3 ROCK inhibitors (ROCKi H1152, Y27632, GSK269962A) (Figures 2F and S2E) . Moreover, inhibition of LIMK downstream of ROCK in A375M2 cells resulted in reduced: p-cofilin levels ( Figure S2F ), cell roundness ( Figure S2G ), p-MLC2 levels ( Figure S2H ), and IL-8 secretion ( Figures S2I) . These data indicate that perturbing actin and myosin dynamics has an impact on secretion.
Our observations were further expanded to the matched melanoma paired cell lines WM983B (metastatic) /WM983A (primary) derived from the same patient . WM983B cells were more rounded with higher p-MLC2 levels compared to WM983A cells (Figure 2G, upper panels) and were found to be more secretory ( Figure 2G , lower panels). On the other hand, WM88 elongated melanoma cells did not secrete any of the cytokines measured ( Figure 2G ). To further asses the role of ROCK-Myosin II, WM983B cells were depleted from MLC2 (Figure 2H, upper panel) or treated with a ROCKi (Figure 2I, upper panel) and were found to secrete significantly less cytokines (Figures 2H and 2I, lower panels) . Similar results were observed when ROCK was inhibited in an additional melanoma cell line WM793B ( Figure S2J ).
Overall, our data show that the secretion of immunomodulatory factors, which are important during melanoma progression, is regulated by ROCK-Myosin II activity in melanoma cells.
Amoeboid Melanoma Cells Induce Tumor-Promoting Macrophages Enrichment in amoeboid melanoma cells and TAMs in the IF of human melanomas (Figure 1 ) suggests a potential communication between cancer cells and macrophages. On the other hand, the secretome of amoeboid melanoma cells is rich in over 20 chemotactic factors (Table S1 ) known to trigger chemotaxis in monocytes, which are the precursors of macrophages. Indeed, migration of human peripheral blood mononuclear cell (PBMC)-derived monocytes and monocytic cell lines (THP-1 and U-937) was increased toward secreted factors (conditioned media [CM]) derived from amoeboid A375M2 versus more elongated A375P cells ( Figure 3A ). The timescales of this assay (2-4 h) (Ancuta et al., 2003) suggest that increased chemotaxis was responsible for increased monocytic migration.
We next addressed whether monocytes could be differentiated into macrophages in response to CM A375M2, as this media was rich in factors (macrophage colony stimulating factor [M-CSF] , IL-4, IL-10, IL-13, TGF-b) that affect monocyte-macrophage commitment. We developed a spectrum of in-vitropolarized macrophages (Gordon, 2003; Mantovani et al., 2004 ) ( Figure 3B ). M-CSF, IL-4, or IL-10 treatment showed increased CD163 + CD206 + expression in macrophages, while HLA-DR + CD86 + macrophages were induced after IFN-g&LPS (Figure 3B) . Specifically, IL-4 induced CD206, IL-10 induced CD163, IFN-g&LPS induced CD86 expression, while HLA-DR expression was similar across treatments ( Figure S3A ). Importantly, CM A375M2 induced CD163 + CD206 + macrophages more efficiently than CM A375P (Figures 3C-3E and S3B). CD206 expression was increased in macrophages induced by CM A375M2 ( Figure 3E ) and comparable to that after IL-4 stimulation ( Figure S3A ). Neither CM A375M2-nor CM A375Ptreated macrophages showed difference in expression levels of classic activation markers: HLA-DR and CD86 (Figures 3F and S3C) . Macrophages induced by CM A375M2, IL-4, .1 fold-increase compared to CM A375P, divided into 3 groups (0-to 300-, 0-to 50-, and 0-to 5-fold). Cyan and red indicate the lowest and highest expression levels, respectively. (C) Concentration of IL-1a, IL-10, TGF-b, and IL-8 in CM A375P or CM A375M2, by ELISA (n = 3). (D) After MLC2 knockdown in A375M2 cells, (left) representative immunoblot for p-MLC2 levels and (right) secreted levels of IL-1a, IL-10, TGF-b, and IL-8 in CM A375M2, by ELISA (n R 3 for IL-1a, IL-8, and TGF-b, n = 2 for IL-10). (E) After ROCK1/2 knockdown in A375M2 cells, (left) representative immunoblots for ROCK1/2 and p-MLC2 levels and (right) secreted levels of IL-1a, IL-10, and TGF-b in CM A375M2 by ELISA (n R 3 for IL-1a and TGF-b, n = 2 for IL-10). Figure S3 and Table S1 . (Eligini et al., 2013) . Cell elongation, characteristic of AAMs (McWhorter et al., 2013) , was profound in CM A375M2-treated macrophages, while minimal after IFN-g&LPS treatment or in untreated monocytes ( Figure 3G ). To characterize the functional role of macrophages-induced by amoeboid melanoma cells, a tumor cell-killing assay was performed ( Figure 3H ). IFN-g&LPS-treated macrophages killed both amoeboid A375M2 and elongated WM88 cells ( Figure 3I ). In contrast, macrophages induced by CM A375M2 supported tumor cell viability ( Figure 3I ). Such observations were expanded to a wider panel of melanoma cells (WM1366, WM793B, WM3854, and WM983A) ( Figure S3E ). To further validate the tumor-promoting role of macrophages-induced by amoeboid melanoma cells, in vivo experiments were performed using A375M2 and WM983B xenografts in SCID mice. Macrophage depletion after clodronate liposome delivery (van Rooijen et al., 1996) resulted in impaired in vivo tumor growth in both A375M2 and WM983B tumors (Figures S3F and S3G) . Depletion of F4/80 + CD206 + cells was confirmed ( Figure S3H ). These data suggest a key role for macrophages in mediating melanoma tumor growth.
We next used serum derived from melanoma patients or healthy donors to treat PBMC-derived monocytes ( Figure 3J ). Melanoma-patient-derived sera induced higher levels of CD163 + CD206 + macrophages compared to healthy-donorderived sera, while HLA-DR and CD86 expression remained unchanged ( Figures 3J-3L ). Thus, melanoma-patient-derived secreted factors induce macrophage polarization comparable to amoeboid melanoma cells.
Overall, our data show that amoeboid melanoma cells with high Myosin II activity can recruit monocytes, differentiate them into macrophages, and functionally educate them to support tumor growth.
AATME Composition Is a Conserved Feature in Melanoma In Vivo
We next assessed whether intrinsically high Myosin II activity in melanoma cells has an impact on macrophage recruitment in vivo. A375M2-EGFP cells (amoeboid and higher Myosin II activity) or A375P-EGFP cells (more elongated and lower Myosin II activity) ( Figures 4A and S4A ) were injected subcutaneously into SCID mice. A375M2 tumors grew faster compared to A375P ones ( Figure 4B ). There was an increase in melanoma cell roundness at the IFs of all tumors ( Figure S4B ). We assigned scores from 0 (low intensity) to 4 (very high intensity) of phospho-MLC2 ( Figures 4C, 4D , and S4C). Overall, Myosin II levels were higher in A375M2 tumors compared to A375P tumors in all areas (Figures 4C, 4D, upper panel, and S4C Figure S4E ), while WM983B tumors had the highest levels of Myosin II (Figures 4K, S4F, and S4G). Similarly, WM983B tumors had the highest F4/ 80 + CD206 + TAM infiltration at the IFs, compared to WM983A tumors ( Figures 4L and 4M ). Notably, A375P versus A375M2 and WM983A versus WM983B showed similar proliferation rates in vitro ( Figure S4H ). Since SCID mice are deficient in B and T cells, amoeboid melanoma cells could induce macrophage polarization in vivo. Altogether, these data suggest that invasive amoeboid melanoma cells with high Myosin II activity educate macrophages to jointly support tumor growth.
Next, we investigated whether amoeboid invasive melanoma cells could retain their secretory memory. Melanoma cells were isolated from the IFs and TBs of A375M2 tumors and cultured ex vivo ( Figure S4I ). Melanoma cells isolated from the IF of A375M2 tumors were more secretory ( Figure S4J ) and induced CD163 + CD206 + macrophages more efficiently ex vivo when compared to their TB counterparts ( Figure S4K) .
Moreover, to ensure that AATME can be generated even in the presence of all immune components, highly metastatic and (D) , mean fluorescence intensity (MFI) for CD206 (E) , and %HLA-DR + CD86 + macrophages (F), after treatment with CM A375P, CM A375M2, or culture media only (-) (n = 5;5 different healthy donors). (G) Quantification of macrophage morphology (see also Figure S3D ) (n = 3;3 different healthy donors). (H) Schematic shows macrophage cytotoxicity assay. (I) Fold change of dead tumor cells (A375M2 or WM88) in co-cultures with PBMC-derived monocytes treated with CM A375M2 or IFN-g&LPS. Data are presented as fold change versus the control untreated monocytes. Log2 scale is presented in y axis (n = 6;6 different healthy donors for A375M2 co-cultures and n = 2;2 different healthy donors for WM88 co-cultures). (J) (Top) Schematic shows TAMs induction in vitro with serum from melanoma patients and (bottom) representative FACS dot plots from one donor showing %CD163 + CD206 + and %HLA-DR + CD86 + macrophages after treatment with healthy volunteer's serum or melanoma patient's serum. (K and L) Number of (K) CD163 + CD206 + and (L) HLA-DR + CD86 + macrophages after treatment with healthy volunteer's serum or melanoma patient's serum (n = 3;3 different healthy donors. Sera from n = 10 healthy volunteers, n = 23 melanoma patients, each dot represents a different treatment). In (A) , (B) , (D)-(G), (I), (K) , and (L), graphs and dot blots show mean ± SEM. In (A) , (B) , and (D)-(G), one-way ANOVA with Tukey or Bonferroni (for G) post hoc tests are shown. In (I), t test is shown. In (K) and (L), t test with Welch's correction is shown. Nonsignificant p > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S3 and Tables S1 and S2. amoeboid B16F10 cells were injected into immunocompetent C57BL/6J mice. We observed rounded melanoma cells (Figure S4L) with high Myosin II levels ( Figure 4N ) and increased F4/80 + CD206 + TAMs at the IFs (Figures 4O and S4M ). To closely recapitulate the physiological development of melanoma TME, we used an orthotopic model in which amoeboid 5555 cellsderived from a BRAF V600E mouse model (Dhomen et al., 2009 )-were injected intradermally into C57BL/6J mice. As in previous models, IFs of 5555 tumors were rich in rounded cancer cells ( Figure S4N ) with increased Myosin II activity ( Figure 4P ) and F4/80 + CD206 + TAM infiltration ( Figures 4Q and S4O ). Overall, these results suggest that AATME is a conserved feature in several in vivo melanoma tumor models.
Blocking Myosin II Activity in Melanoma Cells Reprograms Macrophages
We next investigated whether ROCK-Myosin II axis in amoeboid cancer cells is responsible for polarizing macrophages. Monocytes were treated with CM from ROCK-inhibited A375M2 cells using 3 different ROCK inhibitors ( Figure 5A ). ROCK-inhibited A375M2 cells could not induce CD163 + CD206 + macrophages (specifically CD206 expression) compared to control (Figures 5B, S5A, and S5B). HLA-DR and CD86 expression did not change ( Figures S5C and S5D ). In all cases, ROCK-inhibited A375M2 cells had lowered p-MLC2 levels ( Figure S5E ). Similarly, A375M2 cells were less efficient in inducing CD163 + CD206 + macrophages after MLC2 RNAi transfection ( Figure 5C ), while HLA-DR + CD86 + macrophages did not change ( Figure S5F ). TAMs can secrete immunosuppressive factors, such as TGF-b and IL-10 (Pollard, 2004) . Macrophages induced by CM A375M2 secreted high levels of TGF-b and IL-10 ( Figures S5G and S5H ). Tumor necrosis factor (TNF)-a, a key feature of classically activated macrophages, was undetectable (data not shown). Furthermore, monocytes treated with melanoma-patientderived sera differentiated into macrophages, which also secreted higher levels of IL-10 compared to monocytes treated with sera from healthy donors (Figure S5I) , showing that this is a feature of melanoma-associated macrophages. Moreover, monocytes treated with CM from ROCK-inhibited A375M2 cells differentiated into macrophages that secreted significantly less TGF-b and IL-10 ( Figures S5G and S5H ). Of note, macrophages in all experimental conditions were competent for phagocytosis and sensitive to cytochalasin D ( Figure S5J ). These data confirm that ROCK-Myosin II activity in melanoma cells influences macrophage functional polarization.
We have shown in Figure 1 that AAMs are found in proximity of blood vessels and AAMs can promote endothelial cell survival (Chen et al., 2011) . Indeed, macrophages induced by CM A375M2 sustained endothelial cell growth in HMVECs (human microvascular endothelial cells) and HUVECs (human umbilical vessel endothelial cells) more efficiently than macrophages treated with CM from ROCK-inhibited A375M2 cells (Figures  5D) . Overall, our data show that decreasing Myosin II activity in cancer cells leads to phenotypic and functional macrophage reprograming.
To confirm the role of ROCK-Myosin II activity in controlling AATME in vivo, 5555 cells were pre-treated with ROCKi ex vivo and subsequently injected in the dermis of C57BL/6J mice without any further ROCKi treatment ( Figure 5E ). 8 days postinjection, we observed that control tumors generated AATME ( Figures S5K and S5L ). Importantly, ROCKi pre-treated 5555 cells were not able to increase Myosin II levels or recruit F4/ 80 + CD206 + TAMs in the IFs of tumors as efficiently as controls ( Figures S5K and S5L ). 14 days post-injection, melanoma cells had invaded the dermis using amoeboid invasion ( Figure 5F ). At this time point, tumors in the ROCKi pre-treated group displayed pronounced loss of invading amoeboid melanoma cells (Figures 5G-5I) and a reduction in F4/80 + CD206 + TAMs (Figure 5J ). The two groups grew similarly in vitro, but ROCKi pre-treated group displayed a clear growth disadvantage in vivo ( Figures S5M and S5N) . These data suggest that Myosin II activity triggers AATME early on in tumorigenesis, while AATME is further supported during tumor development by amoeboid invasive melanoma behavior.
To extend our observations to the clinical setting, in which drugs are administered systemically in established tumors, mice harboring A375M2-EGFP tumors were treated with ROCKi ( Figures 5K-5N ). Similar to the pre-treatment setting, reduced tumor growth after systemic ROCKi treatment ( Figure 5K ) was associated with loss of melanoma cell roundness ( Figure 5L ), decreased F4/80 + CD206 + TAM infiltration ( Figure 5M ), and decreased vasculature ( Figure 5N ) in the IFs.
Overall, we suggest that AATME composition in vivo is dependent on ROCK-Myosin II activity in melanoma cells located in the IF. Inhibition of ROCK-Myosin II in melanoma cells hinders the generation of tumor-supportive microenvironments.
Myosin II Activity in Melanoma Cells Is Self-Perpetuated via Secreted IL-1a-Induced NF-kB Activation We have identified high levels of protein secretion as a characteristic of amoeboid melanoma cells. To assess whether protein secretion could affect Myosin II activity itself, A375P cells were treated with CM A375M2 and displayed increased: cell roundness ( Figure 6A To understand which signaling pathways were linked to the amoeboid secretory phenotype, GeneGo MetaCore analysis was performed using the protein array data ( Figure 2B ). Amoeboid melanoma cells secrete factors that are part of a network centered on NF-kB ( Figure 6C ), while the second enriched network was centered on STAT3 (data not shown). NF-kB family members RELA (p65), RELB, and REL (c-Rel) contain transactivation domains. NFKB1 (p105) and NFKB2 (p100) encode longer proteins processed to the shorter DNA-binding forms p50 and p52. Phosphorylation of IkBa by the IKK complex enables dissociation from the NF-kB complex (p65/p50) with nuclear translocation of the latter (Perkins, 2012) . To test whether protein secretion mediates NF-kB activity, A375P cells were treated with CM from A375M2 cells and displayed increased p-IkBa levels ( Figure 6D ). Conversely, depletion of MLC2 in A375M2 cells led to decreased p-IkBa levels ( Figures 6E and 6F) suggesting that Myosin II regulates NF-kB activity. Moreover, amoeboid A375M2 melanoma cells have intrinsically high NF-kB activity (p65 nuclear translocation) compared to more elongated A375P cells ( Figure 6G) . These data show that amoeboid cells sustain NF-kB activity in an autocrine and paracrine manner.
We have shown that IL-1a and IL-8 secretion is regulated by ROCK-Myosin II (Figure 2) , while NF-kB can be activated by either of these factors (Grivennikov and Karin, 2010) . We hypothesized that ROCK-Myosin II activity could regulate NF-kB activation via either IL-1a or IL-8. CM from A375M2 cells induced p65 nuclear translocation in A375P cells ( Figures 6H and S6D , upper panel). However, blocking IL-1a, but not IL-8, in CM A375M2 abolished these effects in A375P cells (Figures 6H and S6D, upper panel) . To further understand whether secreted IL-1a itself had a role in controlling amoeboid features, A375P cells were treated with CM A375M2 in which IL-1a had been blocked. Blocking secreted IL-1a led to loss of cell roundness induced by CM A375M2, whereas blocking IL-8 had no effect ( Figures  6I and S6D, lower panel) . These data show that Myosin II activity in amoeboid melanoma cells regulates NF-kB activation via secreted IL-1a and conversely, IL-1a perpetuates the amoeboid phenotype.
We have shown that IL-1a supports both NF-kB activity and amoeboid phenotype. We hypothesized that NF-kB itself transcriptionally controls expression of secreted factors in CM A375M2 ( Figure 6C ) that induce an amoeboid phenotype (Figure 6A ). A375M2 cells depleted from NFKB1 lost cell roundness and p-MLC2 cortical levels (Figures 6J, 6K, and S6E ). Blockade of IKKb activity led to inhibition of IkBa phosphorylation in A375M2 cells ( Figure S6F ) and an IKKb inhibitor (IKKbi) yielded similar results as NFKB1 RNAi depletion ( Figures S6G and  S6H) . Thus, IKKb/NF-kB supports Myosin II activity in amoeboid melanoma cells generating a positive feedback loop. To further understand this signaling network, we studied the kinetics of this process. Cell roundness and p-MLC2 levels were decreased in a time-dependent manner using either or IKKbi (Figures S6L-S6N ). However, ROCK inhibition resulted in earlier changes compared to IKKb inhibition, suggesting that NF-kB affects Myosin II activity indirectly at later time points via transcriptional mechanisms controlling cytokine expression, while ROCK regulates Myosin II activity directly.
In summary, ROCK-Myosin II activity and NF-kB establish a positive feedback loop initiated by ROCK regulation of IL-1a and perpetuated and amplified by IL-1a/IKKb/NF-kB supporting amoeboid behavior in return ( Figure 6L ).
NF-kB Cross-Talk with ROCK-Myosin II in Amoeboid Melanoma Cells Educates the Tumor Microenvironment
We have shown that melanoma cells acquire amoeboid features that can be perpetuated by secretion via a cross-talk with NF-kB. Over 20 chemokines (Table S1 ) and several cytokines secreted by amoeboid cells were connected to NF-kB ( Figure 6C ) pointing at this transcription factor as a master regulator of the effects exerted by amoeboid cells on TME. In fact, NFKB1 depletion in A375M2 cells resulted in CM with decreased chemotactic potential toward monocytic cells ( Figure S7A ). Moreover, depletion of NFKB1 in amoeboid melanoma cells reduced Myosin II activity ( Figure 7A , left panels), secretory potential and macrophage polarization ( Figure 7A, right panel) . These effects were comparable to MLC2 depletion via RNAi ( Figure 7A ). These data show that ROCK-Myosin II regulates macrophage polarization mainly via cytokines connected to NF-kB network ( Figure 6C ). Importantly, MLC2 and NFKB1 depletion in melanoma cells resulted in decreased CD206 in macrophages ( Figure S7B ). Among the cytokines in our panel, IL-4 induced the highest levels of CD206 expression ( Figure S3A ). Importantly, we could rescue the defects in macrophage polarization after NFKB1 or MLC2 depletion upon addition of IL-4 ( Figure 7A, right panel) . Therefore, the cross-talk between ROCK-Myosin II and NF-kB helps melanoma cells at the IF polarize macrophages via secreted factors.
Once amoeboid cells acquire high levels of Myosin II at the IF, they invade the dermis (Figures 5F and 5G ). Such cancer cells could successfully colonize distant metastatic sites, where they need to extravasate (Reymond et al., 2013) . At this stage, endothelial cell-cancer cell communication is crucial (Joyce and Pollard, 2009) . Since the amoeboid secretome is rich in factors controlling vascular permeability ( Figure 2B ), we hypothesized that amoeboid cells could regulate the endothelium via secretion. In fact, abnormal endothelium and vessel leakiness are characterized by inter-endothelial gaps (Garcia et al., 1995; Hashizume et al., 2000) . Endothelial cell monolayers recapitulating established blood vessels were treated with CM A375M2 or CM A375P ( Figure S7C, upper panel) , and inter-endothelial gap formation was favored when HMVECs were treated with CM A375M2 compared to CM A375P ( Figures S7C and S7D ). This was accompanied by decreased vascular endothelial (VE)-cadherin junctional index ( Figures S7C and S7D, lower panel) . CM A375M2-induced effects were lost if HMVECs were treated with CM derived from ROCK1/2-depleted or NFKB1-depleted A375M2 cells ( Figures 7B and 7C, right panel) . In these conditions, A375M2 had lowered Myosin II levels ( Figure 7C , left panel).
Cytoskeletal changes in endothelial cells affect endothelial integrity (Giannotta et al., 2013) . A phospho-antibody array (141 cytoskeletal regulators) was used to measure changes in endothelial cells ( Figures 7D and S7E ). HMVECs treated with CM A375M2 ROCK1/2-depleted cells showed decreased levels of phospho-proteins ( Figures 7D and S7E ) regulating vascular permeability (MEK, Src, PKA, and MLC2) (Kumar et al., 2009) were measured ( Figures 7D and S7E ). Furthermore, we found reduced endothelial permeability in HMVECs treated with CM from A375P cells compared to A375M2 cells ( Figure S7F , left panel). Similar effects were observed in HMVECs when treated with CM from A375M2-ROCK1/2 or NFKB1-depleted (Figure 7E ), or CM from A375M2 cells treated with ROCKi (Figure S7F, right panel) . In all cases, Myosin II levels in melanoma cells were decreased (Figures 7C, 7F , and S7G). Similar effects were observed in HUVECs ( Figure S7H ). Therefore, cross-talk between ROCK and NF-kB in melanoma cells facilitates endothelial cell cytoskeletal remodeling.
Lung is one of the main sites where melanoma metastasizes (Obenauf and Massague, 2015) , and lung retention assays have been used to measure metastatic colonization abilities (Medjkane et al., 2009; Orgaz et al., 2014) . Importantly, melanoma cells with decreased ROCK-Myosin II ( Figure 7F ) could not alter the permeability of lung capillaries ( Figure 7G ) and were less efficient in colonizing the lung compared to controls ( Figure 7H ). Thus, amoeboid melanoma cells with high Myosin II activity and high secretory potential have an advantage once they reach the metastatic site; they remodel the cytoskeleton of endothelial cells and increase vascular permeability to colonize the lung.
DISCUSSION
ROCK-Myosin II contributes to amoeboid tumor invasion and metastasis in a cell-autonomous manner (Sahai and Marshall, 2003; Sanz-Moreno et al., 2008 . Here, we show that amoeboid melanoma cells educate both the myeloid and the endothelial compartment via secretion, regionally, in the IFs of tumors and later at distant metastatic sites. Thus, we define a new regulatory role for Myosin II dynamics in cancer cells beyond intrinsic control of cell motility.
AAMs compose the bulk of TAMs and are considered to be tumor promoting (Mantovani et al., 2002) . Amoeboid cancer cells induce macrophages that are CD206 high CD163 high HLA-DR + CD86 low and produce IL-10 and TGF-b. Such macrophages support both melanoma cell growth and endothelial cell growth. The ratio of ''amoeboid melanoma-induced macrophages'' over ''tumor-killing macrophages'' will have a positive impact on tumorigenesis.
We show that amoeboid cancer cells retain their secretory potential at later metastatic stages, since they have an advantage during metastatic colonization via disrupting endothelial junctions and increasing endothelial cell permeability. Therefore, amoeboid cancer cells hijack these efficient mechanismstypical of immune cells-to modify the vasculature (Artemenko et al., 2014) .
The secretome of amoeboid melanoma cells is complex and rich in immunomodulatory cytokines, chemokines, and growth factors. We show that amoeboid behavior is sustained via a positive feedback loop between ROCK-Myosin-II-driven secretion and IL-1a/NF-kB signaling, generating a strong circuit of signal amplification. Depletion or inhibition of ROCK-Myosin II activity reduces (1) amoeboid behavior, (2) secreted IL-1a, and (3) NF-kB activation in melanoma cells. Conversely, targeting NF-kB in melanoma cells abolishes amoeboid behavior and their secretory profile resulting in defective macrophage polarization and vascular permeability. While targeting NF-kB in the clinic is challenging (Croghan et al., 2010; Markovic et al., 2005) , ROCK inhibitors are used to treat cerebral vasospasm and intraocular pressure (Feng et al., 2016; Olson, 2008) . ROCK inhibitors decrease invasion in pancreatic cancer (Rath et al., 2017) and improve efficacy of chemotherapy (Vennin and Chin, 2017) . Moreover, ROCKi AT13148 (Sadok et al., 2015) is in clinical trials for solid tumors (ClinicalTrials.gov identifier: NCT01585701). In light of our findings, ROCK-Myosin II inhibition in melanoma cells could also be used to reprogram the innate immune microenvironment.
On the other hand, blocking secreted IL-1a in melanoma cells is sufficient to diminish NF-kB activation and amoeboid features. An FDA-approved antagonist of IL-1R for rheumatoid arthritis has been evaluated for the clinical management of cancer metastasis (Holen et al., 2016) (ClinicalTrials.gov identifier: NCT00072111) and a monoclonal antibody against IL-1a (Hong et al., 2014) is in phase III of clinical trials for colorectal cancer (ClinicalTrials.gov identifier: NCT01767857).
In conclusion, regional distribution of amoeboid melanoma cells with high Myosin II activity can contribute to lack of therapy responses by establishing a tumor-supportive AATME. We propose that, after surgical removal of the primary melanoma lesion, the amoeboid phenotype should be targeted using either ROCKi or IL-1a blocking antibodies as therapies to restrict immunosuppressive microenvironments and metastatic dissemination.
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STAR+METHODS KEY RESOURCES
Generation of EGFP-tagged cell lines pLNT/SFFV EGFP lentivector (1 mg) was transfected into HEK293T along with packaging vectors (p-MD2.VSVg (0.4 mg) and pD8.91 (1 mg)) using Lipofectamine 2000 (7.5 ml/well of a 6-well dish). Media was replaced 6 h after transfection. Media with lentiviruses were collected 48 h after transfection, spun down, filtered (0.45 mm) and added to recipient cell lines (A375P, A375M2, WM983A, WM983B and B16F10). EGFP-positive cells were FACS-sorted and used for subsequent experiments.
Generation of VENUS-5555 cells HEK293T cells on 10 cm 2 dishes were transfected using 2M CaCl 2 , and 2x HBS (51558, Sigma) with lentiviral Venus vector (15 mg), pMD2-VSVg (6 mg), pRSVrev (6 mg) and pMDL-g/p-RRE (6 mg). Supernatants were collected 48 h and 72 h after transfection. For lentiviral transduction, 10 5 5555 cells/well were seeded in 6-well tissue culture dish and infected with VENUS reporter lentiviruses added in suspension using 10 mg/ml Polybrene (107689, Sigma). After 48 h, successfully transduced cells were trypsinised and FACS sorted according to their VENUS expression.
ROCK inhibition and IKKb inhibition
For ROCK inhibition, 1%-FCS media with inhibitors (5 mM H1152 or 10 mM Y27632) was added to cells for 4, 24 or 48 h with re-addition at 24 h. For IKKb inhibition, IKKb inhibitor III (0.5 mM) was used for 24 h. DMSO was used a vehicle in the same concentrations as the inhibitors. For the time-course experiments, the inhibitors were used at the same concentration for all the indicated time-points.
Melanoma secreted media (conditioned media, CM) A375P, A375M2, WM983A, WM983B, WM88 and WM793B (2.5x10 5 cells/well) were seeded in complete DMEM or complete RPMI (+10% FCS) in 6-well plates. Next day cells were washed with PBS (with calcium and magnesium) and were cultured in serum-free (SF) media for 48 h. For inhibitor treatments, H1152 (5 mM), Y27632 (5 mM) or GSK269962A (5 mM) was added in serum-free media and replenished after 24 h. Then media was collected, spin down to eliminate debris and used fresh in subsequent experiments. Recipient cells on collagen matrices were treated with secreted media for 24 h and then cell morphology and p-MLC2 levels were assessed. For the experiments with CM derived from melanoma cells isolated from TB or IF of A375M2 tumors (see also Diagram 1 in Methods S1), CM was generated similarly to above. For experiments using blocking antibodies, A375M2-derived media was pre-incubated with blocking antibodies (anti-IL1a, anti-IL8 and their respective isotype controls (IgG2A and IgG1), 0.75mg/ml) for 1 h at 37 C. Then, media was added to A375P cells seeded on coverslips (1 h treatment, for p65 immunofluorescence) or to A375P cells seeded on top of collagen (24 h treatment, for cell morphology analysis). For macrophage polarization experiments, the secreted media was concentrated using Amicon Ultra-4 Centrifugal Filter Unit with Ultracel-3 membrane (Millipore, Watford, UK). After centrifugation for 45 min at 4000 rpm at 4 C, protein concentration was measured by BCA Protein Assay Kit (Life Technologies).
Transfection and RNAi 2x10 5 melanoma cells/well were seeded on 6-well plates and transfected the next day with 20-40 nM SmartPool or individual OTs (On Target) siRNA oligonucleotides, using Optimem-I and Lipofectamine 2000 (Invitrogen). Non-targeting siRNA was used as control. In case of transfection for siRNA to MYL12B and ROCK1/2, transfected cells were incubated for 24 h and 48 h, respectively, after which they were harvested and re-seeded at 25x10 4 cells/well for conditioned media experiments and serum starved for 48 h.
Human PBMC isolation
Peripheral blood mononuclear cells (PBMC) from healthy donors were obtained from anonymized human buffy coats supplied by the NHS Blood and Transplant (Tooting, London, UK). Buffy coat was diluted with PBS (GIBCO) and PBMC isolation was performed by Lymphoprep density gradient separation (Axis-Shield, Oslo, Norway). MACS technology was used to isolate CD14+ monocytes.
Human CD14+ monocytes isolation
In vitro differentiation of human CD14+ monocytes to macrophages For melanoma conditioned macrophage differentiation, 10 6 CD14+ monocytes per well (6-well dish) were seeded in complete RPMI and incubated in 5% CO 2 at 37 C. On day 3, 50% of the media was replenished with fresh media containing 35 mg/ml of CM derived from A375P, A375M2, H1152-or GSK269962A-treated A375M2 melanoma cells or CM derived from A375M2 depleted from MLC2 (MYL12B) or NFKB1 and monocytes were incubated for 3 additional days. A panel of known stimuli was used as controls of different types of differentiated/polarized macrophages. M-CSF (50 ng/ml), IL-4 (20 ng/ml) or IL-10 (20 ng/ml), or IFN-g (20 ng/ml) plus LPS (100 ng/ml) were added on day 3 to monocytes after media replenishment. CD14+ cells with media only served as control. All cytokines were from Peprotech (London, UK) while LPS (derived from Escherichia coli 0111:B4) was from Sigma (Dorset, UK). For macrophage differentiation with melanoma patient-derived serum (MPS), CD14+ monocytes (10 6 /ml) from healthy PBMC were plated in SF-RPMI and 10% of melanoma patient serum was added per well. Serum from either healthy volunteers (HVS) or human AB pooled serum (Sigma, Dorset, UK), were used as controls in the same volumes. Cells were incubated for 6 days in 5% CO 2 at 37 C. HVS samples were obtained from King's College London and National Institute for Health Research Biomedical Research Centre at Guy's and St Thomas' Hospitals. All sera samples used in these experiments were allogeneic to CD14+ monocytes. See also Table S2 for clinical information.
On day 6, cell supernatants were collected for the detection of cytokines. PBS À/À was added on cells and plates were placed on ice for 20-30 min. Cells were then scrapped using a p1000 pipette and used for phenotypic staining.
Macrophage morphology quantification
Bright-field images from day 6 of cell culture (see also 'In vitro differentiation of human CD14+ monocytes to macrophages' section) were used to analyze macrophage morphology using ImageJ software. Cells were divided into three categories according to their shape: rounded-immature, 'fried-egg' and spindle (Eligini et al., 2013) and one field of view was evaluated per condition. Data from 3 independent experiments with cells from 3 different healthy donors were used.
Zymosan phagocytosis assay in vitro Zymosan A S. cerevisiae fluorescein-conjugated BioParticles (Life Technologies, Paisley, UK) were sonicated (3x20s; 90 ultrasonic watts) to obtain a homogeneous population. Zymosan particles were re-suspended in PBSÀ/À (10 8 particles/ml) and opsonized with an equal volume of human AB pooled serum (Sigma) for 1h at 37 C. Differentiated macrophages were serum-starved for 2 h before starting the assay. Particles were thoroughly washed and added in a ratio of 10:1 (particles:macrophages) to macrophages and incubated for 1 h at 4 C to allow particles to bind on the cells and synchronize the onset of phagocytosis. Then cells were washed to remove unbound particles and incubated for 1 h at 37 C, 5%CO 2 , after which cells were harvested with PBSÀ/À, washed with FACS buffer and fixed in 1% para-formaldehyde to quench phagocytosis. Cells were acquired on a BD FACS CANTO II. As a negative control of phagocytosis, macrophages were treated with 5 mM cytochalasin D (Insight Biotechnology, Wembley UK), which is an inhibitor of actin polymerization-dependent phagocytosis. The inhibitor was added to the relevant wells 1 h before adding the zymosan particles and maintained throughout the assay.
Macrophage cytotoxicity/tumor cell killing assay in vitro Briefly, melanoma target cells (A375M2, WM88, WM1366, WM793B, WM3854 and WM983A) were trypsinized, counted and labeled with CFSE (5 mM) using the CFSE cell division tracker unit from Biolegend following manufacturer's instructions. Both CFSE-labeled melanoma cells and macrophages were washed twice in complete RPMI before the co-culture. Targets (10 4 melanoma cells) were added on macrophages (10 5 macrophages) in a ratio of 1:10 (melanoma targets:macrophages) in complete RPMI and incubated for 48 h in 48-well plates in duplicates. Co-cultured cells were harvested with PBS À/À and washed with FACS buffer. Cells were resuspended in DAPI solution (5 mg/ml) for viability staining and immediately acquired on a BD FACS CANTO II.
Tumor cell isolation from tumor body and IF Tumors were dissected from mice, transferred in falcon tubes with PBS À/À CaCl 2 / MgCl 2 and kept in ice before subjecting to tumor cell isolation. Tumors were sliced in the middle into two parts using a scalpel; one part was kept in 4% formaldehyde solution for 48 h for paraffinization while the second part was used for tumor cell isolation. For the latter, the tumor half was peeled with the use of forceps, a pair scissors and scalpel to collect the peritumoral area which was more transparent, while the tumor core was a solid, darker area. Tumor core and peritumoral area were both collected and chopped into small pieces and incubated with digestion solution (1ml/sample); (Digestion solution: 90ml Liberase TM (Roche), (5 mg/ml), 90ml Liberase TH (Roche), (5 mg/ml), 30ml DNase I (Sigma), (5 mg/ml) and 6 mL HBSS (GIBCO)) at 37 C with shaking. See also Diagram 1 in Methods S1.
Chemotaxis assay
Chemotaxis of human primary peripheral blood monocytes, THP1, U937 was assessed using 6.5-mm Costar Transwell cell culture chamber with polycarbonate membrane (5.0 mm pore) following the manufacturer's protocol. Cell suspensions of 3x10 5 cells/0.1ml in SF-RPMI were loaded in the upper chamber compartment. CM from A375M2 or A375P were loaded in the lower chamber. Migrated cells were counted using a Neubauer Chamber. For chemotaxis of A375M2 or A375P cells, 8.0 mm-pore transwells were used instead, and the cell suspension was of 2x10 5 cells/0.1ml in SF-DMEM.
Transendothelial permeability assay CM from A375P, A375M2 control, or ROCK1/2 or NFKB1-depleted A375M2, or A375M2 cells treated with ROCK inhibitors H1152 (5 mM) or Y27632 (10 mM) for 48 h were collected and added to confluent monolayers of HMVECs on gelatin-coated Transwell filters (Costar). FITC-dextran (0.1 mg/ml) was added to the top chamber. Samples from the lower chamber were removed after 1 h incubation and added to a black 96-well plate. Fluorescence was measured using a microplate analyzer. Each condition was performed in triplicates.
ThermoFisher) was intravenously injected and 10 min later mice were sacrificed. Lungs were extracted, washed with PBS (with calcium/magnesium) twice and fixed with 4% formaldehyde for 16 h at 4 C. Lungs were examined under a confocal microscope (see Immunofluorescence section). Data are presented as % field of area covered by fluorescence (green for cells, red for dextran which represents permeability), n = 5 mice/condition for each experiment, n = 2 independent experiments. maxima'' tool. The process was iterated for all markers used in the analysis (F4/80, CD206, GFP and S100b) (Diagram 2B in Methods S1). All the values were introduced in an Excel file and were standardized to the same area (10 5 mm 2 ). To avoid false positive macrophages (that is cancer cells that were CD206+) we applied a correction factor: subtraction of GFP or S100b signal from CD206 total signal.
Statistical analysis
Statistical analysis was performed using GraphPad Prism (version 6, San Diego California USA). The following statistical tests were used: t test unpaired, t test with Welch's correction, Mann-Whitney test, one-way ANOVA with Tukey post hoc, Kruskal-Wallis with Dunn's multiple comparison test and Wilcoxon matched-pairs signed rank test and Two-way ANOVA-post with Bonferroni post hoc test. All experiments were analyzed with a minimum of three independent repeats. Outliers were excluded using the ROUT method. For column bar or scatter dot plots, error bars are the average ± SEM. Boxplots show min to max values or 10-90 percentile. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Figure S3 . Amoeboid Melanoma Cells with High Myosin II Activity Induce Tumor-Promoting Macrophages, Related to Figure 3 (A) Expression levels (geometric mean of fluorescent intensity, gMFI) of HLA-DR, CD86, CD163 and CD206 in macrophages after treatment with M-CSF (50ng/ml), IL-4 (20ng/ml), IL-10 (20ng/ml), IFN-g & LPS (20ng/ml and 100ng/ml) or culture media only (-) (n = 5; 5 different healthy donors). (B and C) Expression levels (gMFI) of (B) CD163, (C) HLA-DR and CD86, in macrophages treated with CM A375P or CM A375M2 or culture media only (-) (n = 5; 5 different healthy donors). (D) Representative bright-field images of macrophages treated with M-CSF, IL-4, IL-10, IFN-g & LPS or culture media only (-). Blue and red arrows show 'friedegg' and elongated shapes, respectively. Scale bar, 50 mm. (E) Dead tumor targets (WM1366, WM793B, WM3854 and WM983A) upon co-culture with CM A375M2-or IFN-g&LPS-stimulated macrophages. Data are presented as fold change versus the control untreated monocytes. Log2 scale is presented in y axis. (F and G) Tumor volume in (F) A375M2-xenografts and (G) WM983B-xenografts, upon depletion of macrophages via clodronate in SCID mice (n = 6 mice PBS group and n = 5 mice clodronate group). 
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